Posted by Michael Wonder on 28 Mar 2024
Abilify Maintena 960 mg (aripiprazole) approved in the EU as the first once every two months long-acting injectable for the maintenance treatment of schizophrenia
27 March 2024 - Otsuka Pharmaceutical announces that its subsidiary Otsuka Pharmaceutical Europe and Lundbeck announced that the European Commission has approved Abilify Maintena 960 mg (aripiprazole) as a once every two months long-acting injectable formulation for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole.
Aripiprazole once every two months long-acting in injection is a new formulation containing 960 mg aripiprazole provided in a single-chamber pre-filled syringe that does not require reconstitution.
